Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HH-006 in Healthy Volunteers
NCT05275465Phase 1Completed
- Sponsor
- Huahui Health
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis B (HBV) comparing HH-006 with Placebo (2 arms). Primary endpoints: Number of participants with treatment emergent adverse events, Severity of treatment emergent adverse events and 1 more. Started May 2022; status: completed.
02
Drugs
HH-006
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05275465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275465.